Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company advancing novel cancer therapies through its Integrated Discovery Engine. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments.
Track the latest progress on Zentalis' pipeline, including azenosertib (ZN-c3) studies in gynecological cancers and combination therapies. Our news collection features verified updates on regulatory milestones, research collaborations, and scientific presentations – all essential for understanding the company's position in precision oncology.
Key content includes updates on small molecule therapeutic development, biomarker-driven clinical trials, and corporate partnerships. Bookmark this page for real-time access to ZNTL's evolving research landscape and subscribe for notifications about new developments in oncology drug discovery.
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancer, will participate in the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024, at 10:30 a.m. ET.
The event will be virtual, featuring a fireside chat with the management team. A live webcast and archived recording will be available on the company's website.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) reported its financial results for Q1 2024, showcasing progress in azenosertib clinical development plans and a strong cash position. The company highlighted upcoming milestones, corporate updates, and the projected cash runway into mid-2026. Azenosertib shows promise in various tumor types, with multiple data readouts expected in late 2024 and 2025, including results in gynecological cancers.
Zentalis Pharmaceuticals, Inc. announced inducement grants under Nasdaq Listing Rule 5635(c)(4), granting non-qualified stock options to three new employees. The options have an exercise price of $11.31 per share, a 10-year term, and will vest over four years.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
